Literature DB >> 16174284

Role of megalin, a proximal tubular endocytic receptor, in the pathogenesis of diabetic and metabolic syndrome-related nephropathies: protein metabolic overload hypothesis.

Akihiko Saito1, Tetsuro Takeda, Hitomi Hama, Yuko Oyama, Kiyoko Hosaka, Atsuhito Tanuma, Ryohei Kaseda, Mitsuhiro Ueno, Shinichi Nishi, Shinya Ogasawara, Fumio Gondaira, Yoshiki Suzuki, Fumitake Gejyo.   

Abstract

Megalin is an endocytic receptor on the apical membranes of proximal tubule cells (PTC) in the kidney, and is involved in the reabsorption and metabolism of various proteins that have been filtered by glomeruli. Patients with diabetes, especially type 2 diabetes, or metabolic syndrome are likely to have elevated serum levels of advanced glycation end products, liver-type fatty acid binding protein, angiotensin II, insulin and leptin, and renal metabolism of these proteins is potentially overloaded. Some of these proteins are themselves nephrotoxic, while others are carriers of nephrotoxic molecules. Megalin is involved in the proximal tubular uptake of these proteins. We hypothesize that megalin-mediated metabolic overload in PTC leads to compensatory cellular hypertrophy and sustained Na+ reabsorption, causing systemic hypertension and glomerular hyperfiltration via tubuloglomerular feedback, and named this as 'protein metabolic overload hypothesis'. Impaired metabolism of bioactive proteins such as angiotensin II and insulin in PTC may enhance hypertrophy of PTC and/or Na+ reabsorption. Sleep apnoea syndrome, a frequent complication of diabetes and metabolic syndrome, may cause renal hypoxia and result in relative overload of protein metabolism in the kidneys. The development of strategies to identify patients with diabetes or metabolic syndrome who are at high risk for renal metabolic overload would allow intensive treatment of these patients in an effort to prevent the development of nephropathy. Further studies on the intracellular molecular signalling associated with megalin-mediated metabolic pathways may lead to the development of novel strategies for the treatment of nephropathies related to diabetes and metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174284     DOI: 10.1111/j.1440-1797.2005.00453.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  6 in total

1.  Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis.

Authors:  Jorge E Toblli; Gabriel Cao; Jorge F Giani; Margarita Angerosa; Fernando P Dominici; Nestor F Gonzalez-Cadavid
Journal:  Kidney Blood Press Res       Date:  2010-11-11       Impact factor: 2.687

Review 2.  Role of adipocytokines in predicting the development of diabetes and its late complications.

Authors:  Nese Ersoz Gulcelik; Aydan Usman; Alper Gürlek
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

3.  Steroidogenic acute regulatory-related lipid transfer domain protein 5 localization and regulation in renal tubules.

Authors:  Yu-Chyu Chen; Renate K Meier; Shirong Zheng; Syed J Khundmiri; Michael T Tseng; Eleanor D Lederer; Paul N Epstein; Barbara J Clark
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

4.  Significance of urinary full-length megalin in patients with IgA nephropathy.

Authors:  Takuto Seki; Katsuhiko Asanuma; Rin Asao; Kanae Nonaka; Yu Sasaki; Juan Alejandro Oliva Trejo; Hiroyuki Kurosawa; Yoshiaki Hirayama; Satoshi Horikoshi; Yasuhiko Tomino; Akihiko Saito
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

5.  Participation of the SMAD2/3 signalling pathway in the down regulation of megalin/LRP2 by transforming growth factor beta (TGF-ß1).

Authors:  Felipe Cabezas; Pamela Farfán; María-Paz Marzolo
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

6.  Association of metabolic syndrome traits with urinary biomarkers in Japanese adults.

Authors:  Keiko Kabasawa; Michihiro Hosojima; Yumi Ito; Kazuo Matsushima; Junta Tanaka; Masanori Hara; Kazutoshi Nakamura; Ichiei Narita; Akihiko Saito
Journal:  Diabetol Metab Syndr       Date:  2022-01-15       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.